Fluoxetine (Page 5 of 12)
5.14 Fluoxetine and Olanzapine in Combination
When using fluoxetine and olanzapine in combination, also refer to the Warnings and Precautions section of the package insert for Symbyax.6 ADVERSE REACTIONS
When using fluoxetine and olanzapine in combination, also refer to the Adverse Reactions section of the package insert for Symbyax.6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect or predict the rates observed in practice.
Multiple doses of fluoxetine have been administered to 10,782 patients with various diagnoses in U.S. clinical trials. In addition, there have been 425 patients administered fluoxetine in panic clinical trials. Adverse reactions were recorded by clinical investigators using descriptive terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse reactions without first grouping similar types of reactions into a limited (i.e., reduced) number of standardized reaction categories.
In the tables and tabulations that follow, COSTART Dictionary terminology has been used to classify reported adverse reactions. The stated frequencies represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse reaction of the type listed. A reaction was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. It is important to emphasize that reactions reported during therapy were not necessarily caused by it.
The prescriber should be aware that the figures in the tables and tabulations cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and nondrug factors to the side effect incidence rate in the population studied.
Incidence in Major Depressive Disorder, OCD, bulimia, and Panic Disorder placebo-controlled clinical trials (excluding data from extensions of trials) — Table 3 enumerates the most common treatment-emergent adverse reactions associated with the use of fluoxetine (incidence of at least 5% for fluoxetine and at least twice that for placebo within at least 1 of the indications) for the treatment of Major Depressive Disorder, OCD, and bulimia in U.S. controlled clinical trials and Panic Disorder in U.S. plus non-U.S. controlled trials. Table 5 enumerates treatment-emergent adverse reactions that occurred in 2% or more patients treated with fluoxetine and with incidence greater than placebo who participated in U.S. Major Depressive Disorder, OCD, and bulimia controlled clinical trials and U.S. plus non-U.S. Panic Disorder controlled clinical trials. Table 4 provides combined data for the pool of studies that are provided separately by indication in Table 3.
Percentage of Patients Reporting Event | ||||||||
---|---|---|---|---|---|---|---|---|
Major DepressiveDisorder | OCD | Bulimia | Panic Disorder | |||||
1 Incidence less than 1%.2 Includes U.S. data for Major Depressive Disorder, OCD, Bulimia, and Panic Disorder clinical trials, plus non-U.S. data for Panic Disorder clinical trials.3 Denominator used was for males only (N=690 fluoxetine Major Depressive Disorder; N=410 placebo Major Depressive Disorder; N=116 fluoxetine OCD; N=43 placebo OCD; N=14 fluoxetine bulimia; N=1 placebo bulimia; N=162 fluoxetine panic; N=121 placebo panic). | ||||||||
Body System/ Adverse Reaction | Fluoxetine (N=1728) | Placebo (N=975) | Fluoxetine (N=266) | Placebo (N=89) | Fluoxetine (N=450) | Placebo (N=267) | Fluoxetine (N=425) | Placebo (N=342) |
Body as a Whole | ||||||||
Asthenia | 9 | 5 | 15 | 11 | 21 | 9 | 7 | 7 |
Flu syndrome | 3 | 4 | 10 | 7 | 8 | 3 | 5 | 5 |
Cardiovascular System | ||||||||
Vasodilatation | 3 | 2 | 5 | — | 2 | 1 | 1 | — |
Digestive System | ||||||||
Nausea | 21 | 9 | 26 | 13 | 29 | 11 | 12 | 7 |
Diarrhea | 12 | 8 | 18 | 13 | 8 | 6 | 9 | 4 |
Anorexia | 11 | 2 | 17 | 10 | 8 | 4 | 4 | 1 |
Dry mouth | 10 | 7 | 12 | 3 | 9 | 6 | 4 | 4 |
Dyspepsia | 7 | 5 | 10 | 4 | 10 | 6 | 6 | 2 |
Nervous System | ||||||||
Insomnia | 16 | 9 | 28 | 22 | 33 | 13 | 10 | 7 |
Anxiety | 12 | 7 | 14 | 7 | 15 | 9 | 6 | 2 |
Nervousness | 14 | 9 | 14 | 15 | 11 | 5 | 8 | 6 |
Somnolence | 13 | 6 | 17 | 7 | 13 | 5 | 5 | 2 |
Tremor | 10 | 3 | 9 | 1 | 13 | 1 | 3 | 1 |
Libido decreased | 3 | — | 11 | 2 | 5 | 1 | 1 | 2 |
Abnormal dreams | 1 | 1 | 5 | 2 | 5 | 3 | 1 | 1 |
Respiratory System | ||||||||
Pharyngitis | 3 | 3 | 11 | 9 | 10 | 5 | 3 | 3 |
Sinusitis | 1 | 4 | 5 | 2 | 6 | 4 | 2 | 3 |
Yawn | — | — | 7 | — | 11 | — | 1 | — |
Skin and Appendages | ||||||||
Sweating | 8 | 3 | 7 | — | 8 | 3 | 2 | 2 |
Rash | 4 | 3 | 6 | 3 | 4 | 4 | 2 | 2 |
Urogenital System | ||||||||
Impotence3 | 2 | — | — | — | 7 | — | 1 | — |
Abnormal ejaculation3 | — | — | 7 | — | 7 | — | 2 | 1 |
Percentage of Patients Reporting Event | ||
---|---|---|
Major Depressive Disorder, OCD,Bulimia, and Panic Disorder Combined | ||
1 Incidence less than 1%.2 Includes U.S. data for Major Depressive Disorder, OCD, bulimia, and Panic Disorder clinical trials, plus non-U.S. data for Panic Disorder clinical trials. | ||
Body System/Adverse Reaction | Fluoxetine (N=2869) | Placebo (N=1673) |
Body as a Whole | ||
Headache | 21 | 19 |
Asthenia | 11 | 6 |
Flu syndrome | 5 | 4 |
Fever | 2 | 1 |
Cardiovascular System | ||
Vasodilatation | 2 | 1 |
Digestive System | ||
Nausea | 22 | 9 |
Diarrhea | 11 | 7 |
Anorexia | 10 | 3 |
Dry mouth | 9 | 6 |
Dyspepsia | 8 | 4 |
Constipation | 5 | 4 |
Flatulence | 3 | 2 |
Vomiting | 3 | 2 |
Metabolic and Nutritional Disorders | ||
Weight loss | 2 | 1 |
Nervous System | ||
Insomnia | 19 | 10 |
Nervousness | 13 | 8 |
Anxiety | 12 | 6 |
Somnolence | 12 | 5 |
Dizziness | 9 | 6 |
Tremor | 9 | 2 |
Libido decreased | 4 | 1 |
Thinking abnormal | 2 | 1 |
Respiratory System | ||
Yawn | 3 | — |
Skin and Appendages | ||
Sweating | 7 | 3 |
Rash | 4 | 3 |
Pruritus | 3 | 2 |
Special Senses | ||
Abnormal vision | 2 | 1 |
1 Includes U.S. Major Depressive Disorder, OCD, bulimia, and Panic Disorder clinical trials, plus non-U.S. Panic Disorder clinical trials. | ||||
Major Depressive Disorder, OCD, Bulimia, and Panic Disorder Combined (N=1533) | Major Depressive Disorder (N=392) | OCD (N=266) | Bulimia (N=450) | Panic Disorder (N=425) |
Anxiety (1%) | — | Anxiety (2%) | — | Anxiety (2%) |
— | — | — | Insomnia (2%) | — |
— | Nervousness (1%) | — | — | Nervousness (1%) |
— | — | Rash (1%) | — | — |
Other adverse reactions in pediatric patients (children and adolescents) — Treatment-emergent adverse reactions were collected in 322 pediatric patients (180 fluoxetine-treated, 142 placebo-treated). The overall profile of adverse reactions was generally similar to that seen in adult studies, as shown in Tables 4 and 5. However, the following adverse reactions (excluding those which appear in the body or footnotes of Tables 4 and 5 and those for which the COSTART terms were uninformative or misleading) were reported at an incidence of at least 2% for fluoxetine and greater than placebo: thirst, hyperkinesia, agitation, personality disorder, epistaxis, urinary frequency, and menorrhagia.
The most common adverse reaction (incidence at least 1% for fluoxetine and greater than placebo) associated with discontinuation in 3 pediatric placebo-controlled trials (N=418 randomized; 228 fluoxetine-treated; 190 placebo-treated) was mania/hypomania (1.8% for fluoxetine-treated, 0% for placebo-treated). In these clinical trials, only a primary reaction associated with discontinuation was collected.
Male and female sexual dysfunction with SSRIs — Although changes in sexual desire, sexual performance, and sexual satisfaction often occur as manifestations of a psychiatric disorder, they may also be a consequence of pharmacologic treatment. In particular, some evidence suggests that SSRIs can cause such untoward sexual experiences. Reliable estimates of the incidence and severity of untoward experiences involving sexual desire, performance, and satisfaction are difficult to obtain, however, in part because patients and physicians may be reluctant to discuss them. Accordingly, estimates of the incidence of untoward sexual experience and performance, cited in product labeling, are likely to underestimate their actual incidence. In patients enrolled in U.S. Major Depressive Disorder, OCD, and bulimia placebo-controlled clinical trials, decreased libido was the only sexual side effect reported by at least 2% of patients taking fluoxetine (4% fluoxetine, <1% placebo). There have been spontaneous reports in women taking fluoxetine of orgasmic dysfunction, including anorgasmia.
There are no adequate and well-controlled studies examining sexual dysfunction with fluoxetine treatment.
Symptoms of sexual dysfunction occasionally persist after discontinuation of fluoxetine treatment.
Priapism has been reported with all SSRIs.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.